Cutthroat Cohen Looks at Demise for Being Soft Supervisor

In April 2008, three months before drug makers Elan Corp. and Wyeth were scheduled to release results of their Alzheimer’s drug trial, two health-care analysts for hedge-fund manager Steven A. Cohen warned their boss in an e-mail that a doctor, who implied he had seen inside information about the trial, said it wasn’t going well.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.